Pharmacology of antiepileptic drugs during pregnancy and lactation

Epilepsy and Behavior

Volumn 11, Issue 3, 2007, Pages 263-269

  Pennell, Page B ^a   Gidal, Barry E ^b   Sabers, Anne ^c   Gordon, Jacki ^d   Perucca, Emilio ^e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d Epilepsy Therapy Development Project   (United States)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptic drugs; Breast milk; Drug safety; Drug treatment; Epilepsy; Lactation; Pharmacokinetics; Pregnancy; Puerperium; Research

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CONTRACEPTIVE AGENT; CYTOCHROME P450 3A4; ESTROGEN; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROGESTERONE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ANEMIA; ARTICLE; BREAST CANCER; BREAST FEEDING; CONGENITAL MALFORMATION; CORRELATION ANALYSIS; DISEASE CONTROL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MILK LEVEL; DRUG MONITORING; DRUG PENETRATION; DRUG SAFETY; DRUG TRANSPORT; ENZYME INDUCTION; EPILEPSY; FEMALE; FETUS DEVELOPMENT; HEALTH CARE ORGANIZATION; HEMATOLOGIC DISEASE; HORMONAL THERAPY; HUMAN; LACTATION; LIVER DYSFUNCTION; MENTAL DEVELOPMENT; METABOLIC DISORDER; METHEMOGLOBINEMIA; NONHUMAN; PATIENT COMPLIANCE; PERINATAL DRUG EXPOSURE; PLACENTAL TRANSFER; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNWANTED PREGNANCY;

ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 35748976539     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2007.08.018     Document Type: Article

References (54)

1. Pennell P.B. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 61 Suppl.2 (2003) S35-S42
2. Sankar R. Teratogenicity of antiepileptic drugs: role of drug metabolism and pharmacogenomics. Acta Neurol Scand 116 (2007) 65-71
3. Back D.J., and Orme M.L. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 18 (1990) 472-484
4. Martinez F., and Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care 12 2 (2007) 97-106
5. Delort L., Kwiatkowski F., Chalabi N., et al. Risk factors for early age at breast cancer onset: the "COSA program" population-based study. Anticancer Res 27 (2007) 1087-1094
6. Tomson T., Svensson J., and Hilton-Brown P. Relationship of interindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther Drug Monit 11 (1989) 533-539
7. Sidhu J., Job S., Singh S., et al. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 61 (2006) 191-199
8. Doose D.R., Wang S.S., Padmanabhan M., et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44 (2003) 540-549
9. Fattore C., Cipolla G., Gatti G., et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40 (1999) 783-787
10. Harden C.L., Herzog A.G., Nikolov B.G., et al. Hormone replacement therapy in women with epilepsy: a randomized double blind, placebo-controlled study. Epilepsia 47 (2006) 1447-1451
11. Reimers A., Helde G., and Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 46 (2005) 342-348
12. Sabers A., Ohman I., Christensen J., et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 61 (2003) 570-571
13. Christensen J., Petrenaite V., Atterman J., et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 48 (2007) 484-489
14. Sidhu J., Job S., Bulsara S., et al. The pharmacokinetic and pharmacodynamic consequences of co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 61 (2006) 191-199
15. Shenfield G.M., and Griffin J.M. Clinical pharmacokinetics of contraceptive steroids: an update. Clin Pharmacokinet 20 (1991) 15-37
16. Galimberti C.A., Mazzucchelli I., Arbasino C., et al. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. Epilepsia 47 (2006) 1569-1572
17. Tomson T., Luef G., Sabers A., et al. Valproate effects on kinetics of lamotrigine in pregnancy and with treatment of oral contraceptives. Neurology 67 (2006) 1297-1299
18. Tomson T. Gender aspects of pharmacokinetics of new and old antiepileptic drugs: pregnancy and breast-feeding. Ther Drug Monit 27 (2005) 718-721
19. Pennell P.B., Newport D.J., Stowe Z.N., et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 62 (2004) 292-295
20. Tran T.A., Leppik I.E., Blesi K., et al. Lamotrigine clearance during pregnancy. Neurology 59 (2002) 251-255
21. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2007; in press.
22. Mazzucchelli I., Onat F., Ozkara C., et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and puerperium. Epilepsia 47 (2006) 504-509
23. Christensen J., Sabers A., and Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 67 (2006) 1497-1499
24. Tomson T., and Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and puerperium. Clin Pharmacokinet 46 (2007) 209-219
25. Tomson T., Palm R., Kallen K., et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 48 (2007) 1111-1116
26. EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP Epilepsy Pregnancy Registry. Neurology 66 (2006) 354-360
27. Dickinson R.G., Hooper W.D., Wood B., et al. The effect of pregnancy in humans on the pharmacokinetics of stable isotope labeled phenytoin. Br J Clin Pharmacol 28 (1989) 17-27
28. Loscher W., and Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76 (2005) 22-76
29. Loscher W., and Schmidt D. Experimental and clinical evidence exists for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47 (2006) 1253-1284
30. Baltes S., Gastens A.M., Fedrowitz M., et al. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52 (2007) 333-346
31. Gedeon C., and Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta 27 (2006) 861-868
32. Ceckova-Novotna M., Pavek P., and Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 22 (2006) 400-410
33. Audus K. Controlling drug delivery across the placenta. Eur J Pharm Sci 8 (1999) 161-165
34. Unadkat J., Dahlin A., and Vijay S. Placental drug transporters. Curr Drug Metab 5 (2004) 125-131
35. Smith J.W., Huisman M.T., van Tellingen O., et al. Absence of pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104 (1999) 1441-1447
36. Mölsä M., Heikkinen T., Hakkola J., et al. Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther 78 (2005) 123-131
37. Weiss J., Dormann S.M., Martin-Facklam M., et al. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305 (2003) 197-204
38. Myllynen P., Pienimaki P., and Vahakangas K. Human placental perfusion method in the assessment of transplacental passage of antiepileptic drugs. Toxicol Appl Pharmacol 207 (2005) S489-S494
39. Bittigau P., Sifringer M., Genz K., et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA 99 23 (2002) 15089-15094
40. American Academy of Pediatrics, Work Group on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 1997;100:1035-9.
41. Healthy People 2010. Washington, DC: US Department of Health and Human Services, Public Health Service; 2000.
42. Ito S. Drug therapy for breast-feeding women. N Engl J Med 343 (2000) 118-126
43. Healthy People 2000 National Health Promotion and Disease Prevention Objectives. Washington, DC: US Department of Health and Human Services, Public Health Service; 1990. DHHS Publ. (PHS) 91-50212.
44. Alcorn J., Lu X., Moscow J., et al. Transporter gene expression in lactating and non-lactating human mammary epithelial cells using real-time RT-PCR. J Pharmacol Exp Ther 303 (2002) 487-496
45. Ito S., and Lee A. Drug excretion into breast milk: overview. Adv Drug Deliv Rev 55 (2003) 617-627
46. Johannessen S.I., Helde G., and Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 46 (2005) 775-777
47. Kuhnz W., Koch S., Helge H., et al. Primidone and phenobarbital during lactation period in epileptic women: total and free drug levels in the nursed infants and their effects on neonatal behavior. Dev Pharmacol Ther 11 (1988) 147-154
48. Kuhnz W., Koch S., Jakob S., et al. Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentrations in nursed infants and clinical status. Br J Clin Pharmacol 18 (1984) 671-677
49. Nau H., Rating D., Hauser I., et al. Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers. Eur J Clin Pharmacol 18 (1980) 31-42
50. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 108 (2001) 776-789
51. Pennell P.B. Is breast milk the best for babies of mothers on levetiracetam?. Epilepsy Curr 6 (2006) 22-24
52. Pennell P.B., Ritchie J.C., Newport D.J., et al. Pharmacokinetics of lamotrigine excretion into human breast milk. Neurology 66 Suppl. 2 (2006) A72-A73
53. Ohman I., Vitols S., and Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy?. Epilepsia 46 (2005) 1621-1624
54. Ohman I., Vitols S., and Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 41 (2000) 709-713